HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

Abstract
Ovarian serous neoplasms can have morphologic overlap with malignant mesothelioma. The distinction is clinically important, yet most studies have failed to identify immunostains that reliably distinguish these 2 tumor types. Recently, transcription factor PAX8 was shown to be a sensitive and relatively specific marker for Müllerian tumors. In addition, some studies suggest that h-caldesmon is sensitive and specific for mesothelioma when compared with serous ovarian tumors. The goal of this study was to evaluate whether PAX8 and h-caldesmon expression can successfully distinguish mesothelioma from serous ovarian tumors. Immunohistochemistry was carried out using PAX8 and h-caldesmon antibodies on archival tissue from 254 ovarian serous tumors and 50 mesothelial tumors. Nuclear and cytoplasmic immunoreactivity were considered positive for PAX8 and h-caldesmon, respectively. PAX8 staining was present in 99% of high-grade serous ovarian carcinomas and all (100%) low-grade ovarian carcinomas and serous borderline tumors; however, only 74% of these cases (188/254) were diffusely positive in more than 50% of tumors cells, and intensity ranged from strong to weak. None of the pleural malignant mesotheliomas were reactive with PAX8. However, 2/23 (9%) peritoneal malignant mesotheliomas showed focal and/or weak staining for PAX8; the remaining cases were negative. Two well-differentiated papillary mesotheliomas and 1 multicystic mesothelioma each showed some staining for PAX8. h-caldesmon was negative in all serous neoplasms and all mesothelial neoplasms, except 1 pleural malignant mesothelioma which showed patchy immunoreactivity. Strong PAX8 staining is highly specific (P<0.00001) for ovarian serous tumors when compared with malignant mesotheliomas of the peritoneum and pleura. The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma.
AuthorsAnna R Laury, Jason L Hornick, Ruth Perets, Jeffrey F Krane, Joseph Corson, Ronny Drapkin, Michelle S Hirsch
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 34 Issue 5 Pg. 627-35 (May 2010) ISSN: 1532-0979 [Electronic] United States
PMID20414098 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Calmodulin-Binding Proteins
  • PAX8 Transcription Factor
  • PAX8 protein, human
  • Paired Box Transcription Factors
Topics
  • Biomarkers, Tumor (metabolism)
  • Calmodulin-Binding Proteins (metabolism)
  • Cystadenocarcinoma, Serous (diagnosis, metabolism)
  • Diagnosis, Differential
  • Female
  • Fluorescent Antibody Technique, Direct
  • Humans
  • Immunoenzyme Techniques
  • Mesothelioma (diagnosis, metabolism)
  • Ovarian Neoplasms (diagnosis, metabolism)
  • PAX8 Transcription Factor
  • Paired Box Transcription Factors (metabolism)
  • Peritoneal Neoplasms (diagnosis, metabolism)
  • Pleural Neoplasms (diagnosis, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: